Latest news : Mabpharm Limited

06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI
27/12/24	Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection)	CI

More news

Press Releases: Mabpharm Limited

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

More press releases

Managers and Directors: Mabpharm Limited

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

More insiders

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

389

Sector

Biotechnology & Medical Research

Calendar

08-28 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
19/08/26	HK$0.4200	0.00%	50,000
18/08/26	HK$0.4200	+5.00%	24,000
17/08/26	HK$0.4000	-4.76%	176,000
14/08/26	HK$0.4200	0.00%	10,000
13/08/26	HK$0.4200	+2.44%	20,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. 12:08:48 19/08/2026 +04			5-day change	1st Jan Change
0.4200 ^HKD	0.00%		0.00%	-16.00%

Market Cap	1.49B 1.73B 221M 189M 177M 162M 305M 21.12B 310M 2.09B 818M 10.59B 829M 811M 35.01B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.7B 1.99B 253M 217M 203M 186M 350M 24.2B 356M 2.39B 937M 12.14B 951M 930M 40.13B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

Current month	+5.00%
1 month	+3.70%
3 months	-17.65%
6 months	-17.65%
Current year	-16.00%

1 week	0.4	0.42
1 month	0.4	0.44
Current year	0.31	0.81
1 year	0.31	0.87
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	0.00%	0.00%	-47.50%	-17.65%	221M
WUXI APPTEC CO., LTD.	-1.90%	+2.37%	+69.11%	+110.88%	73.45B
ARGENX SE	+0.87%	+17.17%	+53.05%	+95.59%	62.99B
INSMED INCORPORATED	+1.71%	-1.44%	+2.66%	+501.29%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	-1.40%	+4.18%	+54.52%	+19.60%	25.42B
BIONTECH SE	+21.96%	+21.90%	+0.51%	+2.50%	23.3B
GENMAB A/S	+2.28%	+7.98%	+42.75%	-12.34%	19.45B
PHARMAESSENTIA CORPORATION	0.00%	-4.11%	+243.99%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.50%	-0.95%	+17.17%	+534.55%	16.53B
EXELIXIS, INC.	+2.39%	+5.96%	+44.04%	+157.77%	13.16B
Average	+2.24%	+2.47%	+48.03%	+181.60%	28.07B
Weighted average by Cap.	+1.63%	+4.38%	+57.02%	+167.96%

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news : Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Course Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	258M 301M 38.36M 32.9M 30.73M 28.19M 53.01M 3.67B 53.88M 363M 142M 1.84B 144M 141M 6.08B	646M 753M 95.98M 82.33M 76.88M 70.53M 133M 9.17B 135M 907M 355M 4.6B 360M 353M 15.21B
Net income	-128M -149M -19.01M -16.3M -15.22M -13.97M -26.27M -1.82B -26.7M -180M -70.34M -911M -71.37M -69.81M -3.01B	57.13M 66.54M 8.49M 7.28M 6.8M 6.24M 11.73M 811M 11.92M 80.22M 31.41M 407M 31.87M 31.17M 1.35B
Net Debt	222M 259M 33.01M 28.32M 26.44M 24.26M 45.62M 3.16B 46.38M 312M 122M 1.58B 124M 121M 5.23B	217M 253M 32.31M 27.71M 25.88M 23.74M 44.65M 3.09B 45.38M 305M 120M 1.55B 121M 119M 5.12B